Albireo Announces Positive Clinical Data on A3309 in Patients with Chronic Idiopathic Constipation

October 8th, 2009 MAIDENHEAD, England - - Data Presented at the 18th EADV Congress add to the Comprehensive Long-Term Data set as Enbrel Reaches Five-Year Anniversary in Treating Patients With Plaque Psoriasis in Europe Data signalling that Enbrel(R) (etanercept) can improve the quality of life for people with psoriasis and psoriatic arthritis were presented at the 18th Congress of the European Academy of Dermatology and Venereology (EADV), as Enbrel(R) (etanercept) reached its five-year anniversary since its approval in Europe as a treatment for psoriasis. People with psoriasis - a distressing skin condition characterised by red scaly patches - can often feel stigmatised as a result of their condition.

September 9th, 2009 EUROPEAN FEDERATION OF CHAPTERS OF THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF PAIN (EFIC) CONGRESS, LISBON - - Year-Long Tracking Survey Demonstrates That 19% Feel That Their Pain has Become Worse 95% of patients are suffering from moderate to severe chronic pain after one year of treatment[1] and only 12% are being prescribed strong opioids, according to a year-long survey presented today at the EFIC congress. The research reveals that more than half of patients' pain levels fail to improve over the course of a year's treatment and for 19%, their pain has become worse.

July 26th, 2009 TURNHOUT, Belgium - Movetis, the GI specialty pharmaceutical company based in Belgium announces today that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) on the European Marketing Authorisation Application (MAA) for its lead product, prucalopride for the treatment of chronic constipation (CC). The prucalopride MAA was submitted to the EMEA in May 2008.

June 29th, 2009 SAN DIEGO - - Results Demonstrate Positive Proof of Mechanism Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM211, the company's oral selective antagonist of the DP2 (also known as CRTH2) receptor.

June 14th, 2009 SAN DIEGO - Amira Pharmaceuticals, Inc. announced today that it will present preclinical data from its LPA1 receptor antagonist program on June 30, 2009 at the Federation of American Societies for Experimental Biology (FASEB) Summer Research Conference in Carefree, Arizona.

June 3rd, 2009 MAIDENHEAD, England - CHMP Recommends Approval of a Continuous Dosing Regimen Option for Enbrel In Plaque Psoriasis, and a New Pre-Filled Pen Delivery Device Today, Wyeth received positive recommendations from the European Committee for Medicinal Products for Human Use (CHMP) for two recent submissions relating to Enbrel(R) (etanercept), the tumour necrosis factor alpha inhibitor treatment for plaque psoriasis, rheumatoid arthritis and other related inflammatory conditions. Enbrel is currently approved for intermittent treatment of adult plaque psoriasis: if approved by the European Commission following the Committee's recommendation, Enbrel will become the first and only biologic treatment indicated for both continuous and intermittent treatment of adult plaque psoriasis.

June 1st, 2009 CHICAGO - Data from 7 prucalopride trials are being presented at the Digestive Disease Week (DDW) in Chicago. They confirm the consistent and predictable efficacy of prucalopride across different patient groups and add more evidence to its favourable cardiovascular and overall safety profile.

May 5th, 2009 EVRY, France - Novagali Pharma, a French pharmaceutical ophthalmic company, announces today that the Company's Investigational New Drug Application (IND) to conduct a Phase III clinical trial of Catioprost(R) (Nova21027), for the treatment of glaucoma has been granted by the U.S. Food and Drug Administration (FDA).

April 19th, 2009 SAN DIEGO - Trial Will Evaluate Safety, Proof of Mechanism of a Potential Oral Antagonist for the Treatment of Asthma and COPD Amira Pharmaceuticals, Inc., announced today the initiation of a Phase I clinical study of AM211, its internally discovered oral drug candidate for the treatment and control of inflammatory and allergic diseases linked to the arachidonic acid pathway. AM211 is an oral, selective antagonist of the receptor DP2, which recent studies have shown to be a potential target for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis.

March 11th, 2009 TURKU, Finland - BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, announced that it has begun a new Phase IIa clinical testing of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology. The double-blind, vehicle-controlled study is designed to evaluate the tolerability, pharmacokinetics, and efficacy of the topical product in a total of 18 subjects with mild to moderate plaque psoriasis.

January 18th, 2009 TORONTO - Abuse and addiction to opioid analgesics, prescribed for chronic pain, is less common than suspected, according to the latest research. In a review study for pain treatment topics, editor of Pain-Topics.org, Stewart B.

November 3rd, 2009 WASHINGTON - A new research has suggested that a common type of chronic diarrhoea may be caused by a hormone deficiency. Researchers from Imperial College London, with collaborators from King's College London and the University of Edinburgh, say their results could help more doctors recognise this type of diarrhoeal illness, and may lead to the development of more effective tests and treatments to help improve the lives of many people suffering with chronic diarrhoea.

January 15th, 2009 WASHINGTON - People with chronic obstructive pulmonary disease (COPD) are nearly twice as likely to be depressed as diabetics. Dutch researchers compared the health characteristics of 999 patients with COPD, 978 patients with diabetes, and 2,494 healthy control subjects.

March 17th, 2009 WASHINGTON - A steroid nasal spray has been found to reduce symptoms of chronic rhinosinusitis, according to a new study led by Indian origin scientist. Researchers led by Neil S.

July 21st, 2009 Contrave is an experimental weight-loss drug developed by Orexigen Therapeutics Inc. It has been shown to significantly aid weight loss in three late-stage clinical trials according to Associated Press reports.

July 23rd, 2009 LONDON - A drunken Romanian man, who was suffering from constipation, decided to solve the problem by stuffing two hammers up his own butt. Viorel Firoiu, 48, then turned up at his local hospital complaining of excruciating stomach pain.

May 6th, 2009 HYDERABAD - MakroCare, a global clinical services firm, provides clinical research support to pharmaceutical, biotechnology, and medical device industries, is taking a lead in the training of professionals for the clinical research industry by providing series of informational through workshop and seminars. Advanced GCP workshop will be held at CHITRAMAYEE Auditorium, State Arts Gallery, Kavuri Hills, Madhapur, Hyderabad on May 15.

March 21st, 2009 WASHINGTON - Vitamin D deficiency might worsen the condition of people suffering from chronic pain, according to a new study. The research from Mayo Clinic has found a link between inadequate vitamin D levels and the amount of narcotic medication taken by patients who have chronic pain.

April 18th, 2009 WASHINGTON - A new nasal delivery technology with fluticasone, developed by OptiNose, has been found effective in treating chronic rhinosinusitis in a Phase II trial. Chronic rhinosinusitis (CRS) is a common disease that severely reduces a patient's quality of life, and has few effective treatments currently available.

October 16th, 2009 LONDON - An international research team has shown that treating HIV-AIDS with interleukin-2 (IL-2) is ineffective. The researchers, therefore, suggest that clinical trials on this compound be stopped.